Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine Augmentation in Resistant Obsessive Compulsive Disorder
IRCT20201004048919N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mirtazapine in refractory obsessive-compulsive disorder (TR-OCD), sponsored by Shiraz University of Medical Sciences. Started Jul 2021; status: completed.
02
Drugs
mirtazapine
03
Conditions
refractory obsessive-compulsive disorder (TR-OCD)
Beyond the preview
Go deeper on IRCT20201004048919N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201004048919N1.